Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer.
Shibaki R, Fujimoto D, Nozawa T, Sano A, Kitamura Y, Fukuoka J, Sato Y, Kijima T, Matsumoto H, Yokoyama T, Miura S, Hata A, Tamiya M, Taniguchi Y, Sugisaka J, Furuya N, Tanaka H, Yamamoto N, Koh Y, Akamatsu H. Shibaki R, et al. Among authors: sugisaka j. J Immunother Cancer. 2024 Feb 15;12(2):e007987. doi: 10.1136/jitc-2023-007987. J Immunother Cancer. 2024. PMID: 38360040 Free PMC article.
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. Horn L, et al. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, De Giglio A, Muzaffar M, Patel SH, Sugawara S, Burkart J, Park W, Chiari R, Sugisaka J, Otterson GA, de Lima Lopes G, Walker PR. Naqash AR, et al. Among authors: sugisaka j. Cancer Immunol Immunother. 2020 Jul;69(7):1177-1187. doi: 10.1007/s00262-020-02536-5. Epub 2020 Mar 5. Cancer Immunol Immunother. 2020. PMID: 32140762 Free PMC article.
Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
Ono K, Ono H, Toi Y, Sugisaka J, Aso M, Saito R, Kawana S, Aiba T, Odaka T, Matsuda S, Saito S, Narumi A, Ogasawara T, Shimizu H, Domeki Y, Terayama K, Kawashima Y, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S. Ono K, et al. Among authors: sugisaka j. Cancer Med. 2021 Jul;10(14):4796-4804. doi: 10.1002/cam4.4045. Epub 2021 Jun 13. Cancer Med. 2021. PMID: 34121358 Free PMC article.
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
Tsuji K, Mizugaki H, Yokoo K, Kobayashi M, Kawashima Y, Kimura N, Yokouchi H, Kikuchi H, Sumi T, Kawai Y, Kobashi K, Morita R, Ito K, Kitamura Y, Minemura H, Nakamura K, Aso M, Honjo O, Tanaka H, Takashina T, Tsurumi K, Sugisaka J, Tsukita Y, Konno S, Oizumi S. Tsuji K, et al. Among authors: sugisaka j. Cancer Sci. 2024 Apr;115(4):1273-1282. doi: 10.1111/cas.16094. Epub 2024 Jan 29. Cancer Sci. 2024. PMID: 38287788 Free PMC article.
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
Tsukita Y, Tozuka T, Kushiro K, Hosokawa S, Sumi T, Uematsu M, Honjo O, Yamaguchi O, Asao T, Sugisaka J, Saito G, Shiihara J, Morita R, Katakura S, Yasuda T, Hisakane K, Miyauchi E, Morita S, Kobayashi K, Asahina H. Tsukita Y, et al. Among authors: sugisaka j. JAMA Oncol. 2024 Apr 1;10(4):439-447. doi: 10.1001/jamaoncol.2023.6277. JAMA Oncol. 2024. PMID: 38451530
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Toi Y, Sugawara S, Kawashima Y, Aiba T, Kawana S, Saito R, Tsurumi K, Suzuki K, Shimizu H, Sugisaka J, Ono H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y. Toi Y, et al. Among authors: sugisaka j. Oncologist. 2018 Nov;23(11):1358-1365. doi: 10.1634/theoncologist.2017-0384. Epub 2018 Jun 22. Oncologist. 2018. PMID: 29934411 Free PMC article.
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y. Toi Y, et al. Among authors: sugisaka j. JAMA Oncol. 2019 Mar 1;5(3):376-383. doi: 10.1001/jamaoncol.2018.5860. JAMA Oncol. 2019. PMID: 30589930 Free PMC article.
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.
Aso M, Toi Y, Sugisaka J, Aiba T, Kawana S, Saito R, Ogasawara T, Tsurumi K, Ono K, Shimizu H, Domeki Y, Terayama K, Kawashima Y, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S. Aso M, et al. Among authors: sugisaka j. Oncologist. 2020 Mar;25(3):e536-e544. doi: 10.1634/theoncologist.2019-0550. Epub 2019 Nov 7. Oncologist. 2020. PMID: 32162801 Free PMC article.
36 results